Two weeks ago, the FDA begged a Texas judge to delay production on the first monthly batch of 55,000 pages of Covid-19 vaccine data submitted to the agency by Pfizer. Originally, the agency was set to produce just 500 pages-per-month.
Now, Pfizer – which just forecast $54 billion in Covid-related sales in 2022, appears to be anticipating some bad news, as evidenced by several redline changes in their Q4 earnings releases.
As Rubicon Capital’s Kelly Brown notes on Twitter, the changes center around disclosures of unfavorable safety data.
For example, in Q4 they added: “or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection.”
This this image shows what Pfizer added to or removed from its earnings report; that’s the stuff in red.
You can see that they added in a warning to shareholders that “further information regarding the quality of pre-clinical, clinical or safety data including audit or inspection” could potentially impact business.
Here are the tweets from Kelly Brown:
There’s more. Pfizer also highlighted “challenges related to public confidence or awareness of our COVID-19 vaccine or Paxlovid [their overpriced Ivermectin knockoff], including challenges driven by misinformation, access, concerns about clinical data integrity and prescriber and pharmacy education.”
This language was not included in their Q3 2021 earnings report.
Finally, Pfizer also warned about “the possibility that COVID-19 will diminish in severity or prevalence, or disappear entirely.“
That would be terrible for shareholders, wouldn’t it?
Pfizer made a grand total of $36.8 billion off of its Covid-19 Vaccine™ in 2021, making it the single greatest-selling year for a pharmaceutical drug in history.
Why would they be worrying about bad news on the horizon?